Screener
Vertex Pharmaceuticals VRTX Business Segments — income (loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other expense, net | — | (17.6) |
| Income before provision for income taxes | 1,252.9 | 730.4 |
| Provision for income taxes | 221.5 | 84.1 |
| Net income | $1,031.4 | $646.3 |
| Net income per common share: | ||
| Basic | $4.06 | $2.52 |
| Diluted | $4.02 | $2.49 |
| Shares used in per share calculations: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vertex Pharmaceuticals's business segments — income (loss)?
- Vertex Pharmaceuticals (VRTX) reported business segments — income (loss) of $1.03B in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — income (loss) changed year-over-year?
- Vertex Pharmaceuticals's business segments — income (loss) increased by 59.6% year-over-year, from $646.3M to $1.03B.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — income (loss)?
- Over 2 years (2022 to 2025), Vertex Pharmaceuticals's business segments — income (loss) has grown at a 9.1% compound annual growth rate (CAGR), from $3.32B to $3.95B.
- What does business segments — income (loss) mean?
- This metric represents the operating profitability of the core pharmaceutical business segment after accounting for all segment-specific revenues and associated operating expenses, including research, development, and commercialization costs. It serves as a primary indicator of the segment's ability to generate sustainable earnings from its drug portfolio and pipeline investments. By isolating this segment, investors can assess the underlying operational health and margin profile of the company's primary therapeutic business independently of corporate-level overhead or non-recurring items.
Ask your AI about Vertex Pharmaceuticals's business segments — income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude